Product image of Insuman Comb 50 Solostar (Insulin Human) supplied by GNH India

Insuman Comb 50 Solostar

Active Ingredient:
Insulin Human
Origin:
EU

Insuman Comb 50 Solostar (Insulin Human)

Insulin Human, the active ingredient in Insuman Comb 50 Solostar, is an insulin presented as a sterile solution for subcutaneous use. It lowers blood glucose by facilitating cellular uptake and is indicated for the management of diabetes mellitus type 1 and type 2 in adults and children requiring insulin therapy.

GNH India supplies Insuman Comb 50 Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation for each shipment.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insuman Comb 50 Solostar provides exogenous insulin to address the insulin‑deficient pathway in diabetes mellitus.

  • Diabetes mellitus type 1: replaces absent endogenous insulin to achieve glycemic control.
  • Diabetes mellitus type 2: supplies basal insulin to complement oral agents and improve glucose targets.
  • Hyperglycemia in insulin‑deficient states: reduces elevated blood glucose when endogenous production is insufficient.

How It Works

  • Insulin Human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling cascades that promote glucose transport into cells, enhance glycogen synthesis, inhibit hepatic gluconeogenesis, and facilitate lipid metabolism, thereby lowering circulating glucose levels.

Side Effects

Insuman Comb 50 Solostar may cause a range of adverse reactions.

Common Side Effects

  • Hypoglycemia: symptoms of low blood sugar such as shakiness, sweating, and confusion.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: increased adipose tissue due to improved glucose utilization.
  • Lipodystrophy: localized thickening or lipoatrophy of subcutaneous tissue.
  • Edema: mild swelling of extremities.
  • Headache: transient mild headache.

Serious or Rare Side Effects

  • Severe hypoglycemia: neuroglycopenic symptoms requiring immediate treatment.
  • Anaphylactic reaction: urticaria, bronchospasm, or anaphylaxis.
  • Insulin antibodies: may alter insulin action and cause resistance.
  • Hypokalemia: low serum potassium levels.
  • Severe allergic dermatitis: extensive skin rash or eczema.
  • Acute insulin resistance: sudden loss of insulin effectiveness.

Precautions & Warnings

When using Insuman Comb 50 Solostar, consider the following precautions.

  • Dose adjustment: individualize based on frequent glucose monitoring and clinical response.
  • Hypoglycemia risk: educate patients on early signs and prompt treatment.
  • Renal impairment: assess kidney function and consider dose reduction.
  • Pregnancy: use only if benefits outweigh potential risks and under medical supervision.
  • Drug interactions: review concomitant medications that may affect glucose levels.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insuman Comb 50 Solostar can interact with several medicines.

Major Interactions (Avoid)

  • Sulfonylureas: combined use may cause severe hypoglycemia.
  • Pramlintide: concurrent administration increases hypoglycemia risk.
  • Beta‑blockers: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: can raise blood glucose, requiring dose adjustment.
  • Corticosteroids: may increase insulin requirements.
  • ACE inhibitors: may potentiate insulin’s glucose‑lowering effect.

Frequently Asked Questions

Insuman Comb 50 Solostar is a human insulin formulation used to replace or supplement endogenous insulin in patients with diabetes mellitus type 1 and type 2. It helps lower elevated blood glucose levels and is prescribed when insulin therapy is required to achieve target glycemic control.

Insulin Human binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake, promote glycogen synthesis, and suppress hepatic glucose production. This coordinated action reduces circulating glucose and provides energy to cells.

The dose of Insuman Comb 50 Solostar is individualized. A qualified prescriber determines the amount, timing and frequency based on the patient’s blood‑glucose readings, body weight, diet, activity level and overall treatment goals.

Safety data are limited. Insulin is generally considered the preferred glucose‑lowering agent in pregnancy when needed, but it should be used only if the expected benefit outweighs any potential risk. Breastfeeding mothers should consult their healthcare provider before use.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain logistics if required) and import documentation.

Insuman Comb 50 Solostar contains human insulin, which has a slower onset and longer duration than rapid‑acting insulin analogues such as lispro or aspart. It is often used for basal coverage, whereas analogues are preferred for mealtime spikes. Choice depends on patient needs, dosing flexibility and physician preference.

Store the product at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at room temperature (up to 25 °C) for a limited period, typically 28 days, as indicated on the label.

The medication is given by subcutaneous injection using a sterile needle or pen device. Common injection sites include the abdomen, thigh, upper arm or buttock. Rotate sites to reduce lipodystrophy, and follow aseptic technique to prevent infection.

The most serious risks are severe hypoglycemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from local rash to anaphylaxis. Patients should be educated to recognize early signs and have rapid‑acting glucose available.

Individuals with a known hypersensitivity to human insulin or any excipients in the formulation should avoid this product. It is also contraindicated in patients experiencing severe hypoglycemia or in whom insulin therapy is not indicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT